Singapore, Sept. 30 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy... Read More
Singapore, Sept. 30 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitax... Read More
Singapore, Sept. 30 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety... Read More
Singapore, Sept. 30 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety an... Read More
Singapore, Sept. 30 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD... Read More
Singapore, Sept. 30 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with or ... Read More
Singapore, Sept. 30 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muval... Read More
Singapore, Sept. 30 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muval... Read More
Singapore, Sept. 30 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy ... Read More
Singapore, Sept. 30 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Ve... Read More